{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Fallopian+Tube+Cancer&page=2", "query": { "condition": "Stage IB Fallopian Tube Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Fallopian+Tube+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T01:35:36.984Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01366183", "title": "Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Assessment of Therapy Complications", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 290, "start_date": "2011-08-15", "completion_date": null, "has_results": false, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 357, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366183" }, { "nct_id": "NCT04196257", "title": "BP1001-A in Patients With Advanced or Recurrent Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Carcinoma, Ovarian Epithelial", "Fallopian Tube Neoplasms", "Endometrial Cancer", "Peritoneal Cancer", "Solid Tumor" ], "interventions": [ { "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)", "type": "DRUG" }, { "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-08-19", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 4, "location_summary": "Silver Spring, Maryland • Detroit, Michigan • Dallas, Texas + 1 more", "locations": [ { "city": "Silver Spring", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04196257" }, { "nct_id": "NCT03907527", "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC V8", "Stage III Ovarian Cancer AJCC V8", "Stage III Primary Peritoneal Cancer AJCC V8", "Stage IIIA Fallopian Tube Cancer AJCC V8", "Stage IIIA Ovarian Cancer AJCC V8", "Stage IIIA Primary Peritoneal Cancer AJCC V8", "Stage IIIA1 Fallopian Tube Cancer AJCC V8", "Stage IIIA1 Ovarian Cancer AJCC V8", "Stage IIIA2 Fallopian Tube Cancer AJCC V8", "Stage IIIA2 Ovarian Cancer AJCC V8", "Stage IIIB Fallopian Tube Cancer AJCC V8", "Stage IIIB Ovarian Cancer AJCC V8", "Stage IIIB Primary Peritoneal Cancer AJCC V8", "Stage IIIC Fallopian Tube Cancer AJCC V8", "Stage IIIC Ovarian Cancer AJCC V8", "Stage IIIC Primary Peritoneal Cancer AJCC V8", "Stage IV Fallopian Tube Cancer AJCC V8", "Stage IV Ovarian Cancer AJCC V8", "Stage IV Primary Peritoneal Cancer AJCC V8", "Stage IVA Fallopian Tube Cancer AJCC V8", "Stage IVA Ovarian Cancer AJCC V8", "Stage IVA Primary Peritoneal Cancer AJCC V8", "Stage IVB Fallopian Tube Cancer AJCC V8", "Stage IVB Ovarian Cancer AJCC V8", "Stage IVB Primary Peritoneal Cancer AJCC V8" ], "interventions": [ { "name": "PRGN-3005 UltraCAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2019-04-30", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Seattle, Washington", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907527" }, { "nct_id": "NCT03297489", "title": "Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma", "Stage I Ovarian Cancer", "Stage IA Ovarian Cancer", "Stage IB Ovarian Cancer", "Stage IC Ovarian Cancer", "Stage II Ovarian Cancer", "Stage IIA Ovarian Cancer", "Stage IIB Ovarian Cancer", "Stage IIC Ovarian Cancer", "Stage III Ovarian Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIC Ovarian Cancer", "Stage IV Ovarian Cancer" ], "interventions": [ { "name": "Diagnostic Microscopy", "type": "PROCEDURE" }, { "name": "Fluorescein Sodium Injection", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2017-11-06", "completion_date": "2021-02-15", "has_results": false, "last_update_posted_date": "2021-10-06", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297489" }, { "nct_id": "NCT02751918", "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Anetumab ravtansine (BAY94-9343)", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 65, "start_date": "2016-06-08", "completion_date": "2019-10-31", "has_results": false, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 3, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751918" }, { "nct_id": "NCT00303888", "title": "Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "idronoxil", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 31, "start_date": "2006-05", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303888" }, { "nct_id": "NCT01764802", "title": "Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Stage I Uterine Sarcoma", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Endometrial Carcinoma", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Epithelial Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IA Primary Peritoneal Cavity Cancer", "Stage IB Cervical Cancer", "Stage IB Endometrial Carcinoma", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Epithelial Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IB Primary Peritoneal Cavity Cancer", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Epithelial Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage IC Primary Peritoneal Cavity Cancer", "Stage II Endometrial Carcinoma", "Stage II Gestational Trophoblastic Tumor", "Stage II Uterine Sarcoma", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIA Primary Peritoneal Cavity Cancer", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIB Primary Peritoneal Cavity Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIC Primary Peritoneal Cavity Cancer", "Stage III Gestational Trophoblastic Tumor", "Stage III Uterine Sarcoma", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Endometrial Carcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cavity Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Endometrial Carcinoma", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cavity Cancer", "Stage IIIC Endometrial Carcinoma", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cavity Cancer", "Breast Cancer" ], "interventions": [ { "name": "behavioral, psychological or informational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "21 Years to 80 Years · Female only" }, "enrollment_count": 100, "start_date": "2010-10", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764802" }, { "nct_id": "NCT00296816", "title": "TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Bevacizumab (Avastin®)", "type": "DRUG" }, { "name": "Docetaxel (Taxotere®)", "type": "DRUG" }, { "name": "Oxaliplatin (Eloxatin®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2006-03", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2012-08-23", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296816" }, { "nct_id": "NCT05271318", "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-refractory Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin" ], "interventions": [ { "name": "TILT-123", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TILT Biotherapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2022-05-17", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 2, "location_summary": "Rochester, Minnesota • New York, New York", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271318" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-06-11T01:35:36.984Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" } ] }